SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

02 May 2024 Evaluate
The revenue zoomed 14.22% to Rs. 1638.17 millions for the quarter ended March 2024 as compared to Rs. 1434.19 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2024 is Rs. -114.61 millions as compared to Net Profit of Rs. 61.05 millions of corresponding quarter ended March 2023Operating Profit saw a handsome growth to 336.13 millions from 173.90 millions in the quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 1638.17 1434.19 14.22 6054.60 5983.40 1.19 6054.60 5983.40 1.19
Other Income 84.64 64.79 30.64 335.01 507.66 -34.01 335.01 507.66 -34.01
PBIDT 336.13 173.90 93.29 1406.68 1409.21 -0.18 1406.68 1409.21 -0.18
Interest 15.31 49.73 -69.21 58.06 100.56 -42.26 58.06 100.56 -42.26
PBDT -90.04 124.17 -172.51 937.76 1308.65 -28.34 937.76 1308.65 -28.34
Depreciation 62.29 39.74 56.74 235.19 151.73 55.01 235.19 151.73 55.01
PBT -152.33 84.43 -280.42 702.57 1156.92 -39.27 702.57 1156.92 -39.27
TAX -37.72 23.38 -261.33 196.13 302.14 -35.09 196.13 302.14 -35.09
Deferred Tax -97.62 -24.68 295.54 -75.49 -42.10 79.31 -75.49 -42.10 79.31
PAT -114.61 61.05 -287.73 506.44 854.78 -40.75 506.44 854.78 -40.75
Equity 104.69 104.15 0.52 104.69 104.15 0.52 104.69 104.15 0.52
PBIDTM(%) 20.52 12.13 69.22 23.23 23.55 -1.35 23.23 23.55 -1.35

Bliss GVS Pharma Share Price

258.35 -0.95 (-0.37%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×